Aster DM Healthcare’s Q2 results show an 85% surge in net profit, hitting ₹108 crore, with a 16% increase in revenue to ₹1,086 crore. This growth sparked an 11% rise in stock prices, indicating strong investor confidence in the company’s performance.
The company’s EBITDA for Q2 saw a 48% surge to ₹233 crore, with the operating EBITDA margin expanding to 21.4% from 16.4% last year. Additionally, the net profit margin improved significantly to 8.9%, up from 5.4%.
Also Read: Rupee Rises Slightly From Record Low – Read More!
In the first half of FY25, Aster DM Healthcare’s revenue from its hospitals and clinics business increased by 20% YoY to ₹2,019 crore. However, the labs and pharmacies segment experienced a 7% decline, bringing in ₹130 crore.
The EBITDA from the hospitals and clinics segment rose 41% YoY to ₹453 crore in H1FY25. Net profit in this segment also grew robustly by 64% YoY to ₹267 crore, with a return on capital employed (RoCE) of 24%.
Also Read: Freshara Agro Ltd Debuts with 16.3% Premium, Read More!
The company maintained its hospital count at 19 but increased its total bed capacity to 4,994, reflecting a slight growth. Outpatient volume also rose by 14% YoY, totaling 1.7 million in H1FY25.
Looking ahead, Aster DM Healthcare plans to expand its bed capacity by an additional 1,800 beds by FY27, aiming for a total of 6,800 beds to accommodate growing demand. Founder Azad Moopen highlighted the growth driven by increased occupancy and revenue per bed.
